top of page

THELMA
OFFICIAL TITLE: T-DM1 AND NON-PEGYLATED LIPOSOMAL DOXORUBICIN IN HER2-POSITIVE METASTATIC BREAST CANCER.

CLINICAL TRIAL DETAILS
PHASE I MULTICENTER CLINICAL TRIAL EVALUATING THE COMBINATION OF TRASTUZUMAB EMTANSINE (T-DM1) AND NON-PEGYLATED LIPOSOMAL DOXORUBICIN IN HER2-POSITIVE METASTATIC BREAST CANCER.
THE PRIMARY GOAL IS TO DETERMINE THE MAXIMUM TOLERATED DOSE (MTD) OF THE COMBINATION OF T-DM1 AND NON-PEGYLATED LIPOSOMAL DOXORUBICIN IN METASTATIC BREAST CANCER (MBC) PATIENTS PREVIOUSLY TREATED WITH TAXANES AND TRASTUZUMAB-BASED THERAPY.
IN ADDITION, PHARMACOKINETIC DATA ON THE COMBINATION OF T-DM1 AND LYPOSOMAL DOXORUBICIN WILL BE OBTAINED.
THELMA AT CLINICALTRIALS.GOV
TUMOR TYPE
PHASE
BREAST
I
24
7
Spain, France, Slovenia
N
SITES
COUNTRY
STATUS
Closing
ESMO 2019 – DOWNLOAD THE POSTER
THELMA SITES

SPAIN
Hospital Universitari Vall D'Hebron
SPAIN
Hospital Universitario Ramón y Cajal
SPAIN
Hospital Clínic i Provincial de Barcelona
FRANCE
Institut Curie
FRANCE
Hôpital Tenon AP-HP
SLOVENIA
Univerzitetni klinicni center Maribor Oddelek za onkologijo
SLOVENIA
Onkološki Inštitut Ljubljana
bottom of page